#USA #New York #NASDAQ #Stock Split #PAVmed

PAVmed Announces Reverse Stock Split

PAVmed Inc. (NASDAQ: PAVM), a prominent player in the medical technology sector, has recently revealed plans for a reverse stock split aimed at ensuring compliance with Nasdaq's listing standards. This strategic move, approved by stockholders during a special meeting held on December 5, 2025, entails a 1-for-30 reverse stock split, effective starting January 2, 2026, at 12:01 AM ET.

Purpose of the Reverse Split

The primary goal behind PAVmed's reverse stock split is to meet the minimum bid price requirement of $1.00 for shares trading on the Nasdaq. By consolidating shares, PAVmed aims to strengthen its stock price and uphold its listing on the Nasdaq Capital Market. Shares will continue to be traded under the ticker symbol 'PAVM' at the opening of the market on the specified date on a split-adjusted basis.

Details of the Split

The approved plan will reduce the total authorized shares from 250 million to 25 million. This adjustment also affects the equity incentive plan, employee stock purchase plan, stock options, and convertible securities, which will see a proportionate reduction regarding the number of shares and exercise prices.

PAVmed confirmed that fractional shares resulting from the reverse split would not be issued. However, any stockholder left with a fractional share will have it rounded up to the nearest whole share. This ensures that all stockholders maintain an equitable position following the split.

Company's Background

PAVmed operates at the forefront of medical technology, focusing on several key areas including medical devices, diagnostics, and digital health solutions. The company is known for its innovative approaches aimed at improving patient outcomes and advancing healthcare technologies.

PAVmed's subsidiary, Lucid Diagnostics Inc., widely recognized for its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, specializes in early detection of esophageal cancer to prevent fatalities associated with the disease. Another subsidiary, Veris Health Inc., employs modern technology for personalized cancer care, including remote monitoring through biologic sensors and external devices. They're also working on a new implantable physiological monitor intended for chemotherapy patients, enhancing their innovative offerings in patient care.

What’s Next?

As the firm embarks on this new chapter following the reverse stock split, it remains focused on meeting market expectations, advancing its product offerings, and addressing the ongoing challenges posed by the volatile healthcare landscape. Stakeholders and investors will be watching closely as PAVmed navigates these changes, ensuring its strategies align with both industry standards and shareholder interests.

For further insights into PAVmed's future plans and initiatives, interested parties can visit PAVmed's official website as well as the pages dedicated to its subsidiaries, Lucid and Veris Health. As always, industry developments and corporate performance updates will play a crucial role in shaping PAVmed's trajectory in the ever-evolving medical technology market.